Who should be treating adolescents and young adults with acute lymphoblastic leukaemia?

European Journal of Cancer

Volumn 39, Issue 18, 2003, Pages 2579-2583

  Jeha, S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adolescents; ALL; AYA; Leukaemia

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; CANCER CELL; CANCER CENTER; CANCER INCIDENCE; CANCER SURVIVAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SENSITIVITY; GENE EXPRESSION; GENE REARRANGEMENT; GROUPS BY AGE; HUMAN; LEUKEMIA CELL; MEDICAL CARE; MEDICAL SPECIALIST; ONCOLOGY; PATIENT COMPLIANCE; PEDIATRICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0345414722     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.09.005     Document Type: Article

References (34)

1. Gaynon P.S., Trigg M.E., Heerema N.A.et al. Children's Cancer Group trials in childhood acute lymphoblastic leukaemia. 1983-1995 Leukemia. 14:2000;2223-2233.
2. Pui C.H., Boyett J.M., Rivera G.K.et al. Long-term results of total therapy studies 11, 12 and 13a for childhood acute lymphoblastic leukemia at St. Jude Children's Research Hospital. Leukemia. 14:2000;2286-2294.
3. Kantarjian H.M., O'Brien S., Smith T.L.et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J. Clin. Oncol. 18:2000;547-561.
4. Larson R.A., Dodge R.K., Burns C.P.et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukaemia. cancer and leukemia group B study 8811 Blood. 85:1995;2025-2037.
5. Pui C.H., Evans W.E. Acute lymphoblastic leukemia. N. Engl. J. Med. 333:1998;605-615.
6. Kaspers G.J., Veerman A.J., Pieters R.et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 90:1997;2723-2729.
7. Faderl S., Kantarjian H.M., Talpaz M., Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 91:1998;3995-4019.
8. Roberts W.M., Rivera G.K., Raimondi S.C.et al. Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Lancet. 343:1994;331-332.
9. Arico M., Valsecchi M.G., Camitta B.et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med. 342:2000;998-1006.
10. Pui C.H., Frankel L.S., Carroll A.J.et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23). a collaborative study of 40 cases Blood. 77:1991;440-447.
11. Bloomfield C.D., Secker-Walker L.M., Goldman A.I.et al. Six year follow up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet. Cytogenet. 40:1989;171-185.
12. Jeha S., Kantarjian H. Treatment of acute lymphoblastic leukemia in adolescents and young adults. Pui C.-H. Current Clinical Oncology: Treatment of Acute Leukemias: New Directions for Clinical Research. 2002;Humana Press, Totowa, NJ.
13. Hoelzer D., Thiel E., Loffler H.et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 71:1988;123-131.
14. Zhang L., Taub J.W., Williamson M.et al. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia. relationship to immunophenotype and ploidy Clin. Cancer Res. 4:1998;2169-2177.
15. Whitehead V.M., Vuchich M.J., Lauer S.J.et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia. a Pediatric Oncology Group study Blood. 80:1992;1316-1323.
16. Goker E., Lin J.T., Trippett T.et al. Decreased polyglutamination of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia. 7:1993;1000-1004.
17. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:1989;137-171.
18. Ivy S.P., Olshefski R.S., Taylor B.J., Patel K.M., Reaman G.H. Correlation of P-glycoprotein expression and function in childhood acute leukemia. A Children's Cancer Group study Blood. 88:1996;309-318.
19. Schiffer C.A. Differences in outcome in adolescents with acute lymphoblastic leukemia. a consequence of better regimens? Better Doctors? Both? J. Clin. Oncol. 21:2003;760-761.
20. Hoelzer D. Acute lymphoblastic leukaemia-progress in children, less in adults. N. Engl. J. Med. 329:1993;1343.
21. Nachman J., Sather H.N., Buckley J.D.et al. Young adults 16-21 years of age at diagnosis entered on Children's Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Cancer. 71:1993;3377-3385.
22. Pinkel D., Simone J., Hustu H.O., Aur J.A. Nine years' experience with "total therapy" of childhood acute lymphocytic leukemia. Pediatrics. 50:1972;246-251.
23. Simone J.V., Aur R.J., Hustu H.O., Verzosa M. Acute lymphocytic leukemia in children. Cancer. 36:1975;770-774.
24. Poplack D.G., Reaman G. Acute lymphoblastic leukemia in childhood. Pediatr. Clin. North Am. 35:1988;903-932.
25. Maloney K.W., Shuster J.J., Murphy S., Pullen J., Camitta B.A. Long-term results of treatment studies for childhood acute lymphoblastic leukaemia. Pediatric Oncology Group studies from 1986-1994 Leukemia. 14:2000;2276-2285.
26. Pui C.H., Boyett J.M., Rivera G.K.et al. Long-term results of total therapy studies 11, 12 and 13a for childhood acute lymphoblastic leukemia at St. Jude Children's Research Hospital. Leukemia. 14:2000;2286-2294.
27. Schrappe M., Reiter A., Zimmermann M.et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 14:2000;2205-2222.
28. Smith M., Arthur D., Camitta B.et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J. Clin. Oncol. 14:1996;18-24.
29. Gee T.S., Haghbin M., Dowling M.D. Jr., Cunningham I., Middleman M.P., Clarkson B.D. Acute lymphocytic leukemia in adults and children. differences in response with similar therapeutic regimens Cancer. 37:1976;1256-1264.
30. Stock W., Sather H., Dodge R.K., Bloomfield C.D., Larson R.A., Nachman J. Outcome of adolescents and young adults with ALL. A comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens Blood. 96:2000;467a.
31. Boissel N., Auclerc M.-F., Lhéritier V.et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J. Clin. Oncol. 23:2003;774-780.
32. Schauer P., Arlin Z.A., Mertelsmann R.et al. Treatment of acute lymphoblastic leukemia in adults. results of the L-10 and L-10M protocols J. Clin. Oncol. 1:1983;462-470.
33. Hussein K.K., Dahlberg S., Head D.et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood. 73:1989;57-63.
34. Radford J.E. Jr., Burns C.P., Jones M.P.et al. Adult acute lymphoblastic leukemia. results of the Iowa HOP-L protocol J. Clin. Oncol. 7:1989;58-66.